Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.
Atherosclerosis
Atherosclerosis
Article
Statins and Insulin Resistance
Read time: 1h 1m 1s
About
Media
Watch time: 4m 53s
Watch time: 4m 57s
Watch time: 8m 2s
Watch time: 3m 25s
Watch time: 4m 43s
Watch time: 4m 14s
Watch time: 7m 48s
Watch time: 7m 44s
Watch time: 10m 34s
Watch time: 9m 40s
Articles
New Insights on Simvastatin and Ezetimibe in a Single Tablet
Citation:
European Cardiovascular Disease 2007;3(1):12–5
- Views:
326
- Downloads:
0
Overview to Antihypertensive and Lipid-lowering Therapies and Patient Care
Citation:
US Cardiology 2006;3(2):18–9
- Views:
65
- Downloads:
0
Plaque Vulnerability and Related Coronary Event Prediction by Virtual Histology
Citation:
Interventional Cardiology 2006;1(1):17-9
- Views:
155
- Downloads:
0
Reducing the Threat of Vascular Disease in Patients with Hypertension and Hyperlipidemia by Addressing Poor Adherence
Citation:
US Cardiology 2006;3(2):22–3
- Views:
69
- Downloads:
0